Furoclav 250 – Cefuroxime Axetil & Clavulanic Acid combination is indicated in-
- Pharyngitis and/or tonsillitis
- Acute bacterial otitis media
- Acute bacterial maxillary sinusitis
- Lower respiratory tract infections including pneumonia
- Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis
- Skin and Skin-Structure Infections
- Urinary tract infections
- Bone and Joint infections
- Gonorrhea: Uncomplicated and disseminated gonococcal infections
- Early Lyme disease (erythema migrans)
- Switch therapy (injectable to oral) after surgery when patient’s condition is improved.
Second generation Cephalosporins
Furoclav 250- Cefuroxime is one of the bactericidal second generation cephalosporin antibiotics, which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains. It is indicated for the treatment of infections caused by sensitive bacteria.
Clavulanic acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta-lactamase enzymes.
Clavulanic acid protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.
Pharyngitis or Tonsillitis: 250 mg twice daily for 5-10 days
Acute bacterial maxillary sinusitis: 250 mg twice daily for 10 days
Acute bacterial exacerbation of chronic bronchitis: 250-500 mg twice daily for 10 days
Secondary bacterial infections of acute bronchitis: 250-500 mg twice daily for 5-10 days
Community acquired pneumonia: 250-500 mg twice daily for 5-10 days
Uncomplicated skin & skin-structure infections: 250-500 mg twice daily for 10 days
Multidrug resistant typhoid fever: 500 mg twice daily for 10-14 days
Uncomplicated urinary tract infection: 250 mg twice daily for 7-10 days
Uncomplicated gonorrhea: 1000 mg once single dose
Lyme disease: 500 mg twice daily for 20 days
Furoclav 250- Cefuroxime & Clavulanic Acid may be administered without regard to meals.
Probenecid: Concomitant administration of probenecid with Cefuroxime increases the area under the serum concentration versus time curve by 50%. The peak serum Cefuroxime concentration after a 1.5 gm single dose is greater when taken with 1 gm of probenecid than without probenecid.
Antacids: Drugs that reduce gastric acidity may result in a lower bioavailability of Cefuroxime and Clavulanic acids compared with that of fasting state and tend to cancel the effect of postprandial absorption.
Oral contraceptives: In common with other antibiotics, Cefuroxime may affect the gut flora, leading to lower estrogen re absorption and reduced efficacy of combined oral estrogen/ progesterone.
It is contraindicated in patients with known allergy to Cefuroxime and Clavulanic acid or to the cephalosporin group of antibiotics.
Generally Cefuroxime and Clavulanic acid are well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur.
Pregnancy & Lactation
Both Cefuroxime and Clavulanic acid are pregnancy category B. Cefuroxime is excreted in human milk; consideration should be given to discontinuing nursing temporarily during treatment with Cefuroxime.
Furoclav 250- Cefuroxime should be given with caution to patients receiving concurrent treatment with potent diuretics because these diuretics are suspected of adversely affecting renal function. Cefuroxime, as with other broad-spectrum antibiotics, should be prescribed with caution in individuals with a history of colitis.
Symptoms: Overdosage of Cefaclav can cause cerebral irritation leading to convulsions.
Management: Serum levels of Cefaclav can be reduced by haemodialysis and peritoneal dialysis.
Should be kept in a cool (15–30°C) and dry place and protected from light.
If you need any assistance/consultation, please do not hesitate to contact us.